# APPENDIX C. KEY TO ACRONYMS

**Updated:** October 27, 2026
**Reviewed:** October 27, 2026

## Drug Name Abbreviations

| Abbreviation | Definition |
|---|---|
| 3TC | lamivudine |
| ABC | abacavir |
| ATV | atazanavir |
| ATV/c | atazanavir/cobicistat |
| ATV/r | atazanavir/ritonavir |
| BIC | bictegravir |
| CAB | cabotegravir |
| CAB-LA | long-acting cabotegravir |
| COBI or c | cobicistat |
| d4T | stavudine |
| ddC | zalcitabine |
| ddI | didanosine |
| DLV | delavirdine |
| DOR | doravirine |
| DRV | darunavir |
| DRV/c | darunavir/cobicistat |
| DRV/r | darunavir/ritonavir |
| DTG | dolutegravir |
| EFV | efavirenz |
| ETR | etravirine |
| EVG | elvitegravir |
| EVG/c | elvitegravir/cobicistat |
| FPV | fosamprenavir |
| FPV/r | fosamprenavir/ritonavir |
| FTC | emtricitabine |
| FTR | fostemsavir |
| IBA | ibalizumab or ibalizumab-uiyk |

| Abbreviation | Definition |
|---|---|
| IDV | indinavir |
| ISL | islatravir |
| ISL-TP | islatravir-triphosphate |
| LA CAB/RPV | long-acting cabotegravir plus rilpivirine |
| LEN | lenacapavir |
| LPV | lopinavir |
| LPV/r | lopinavir/ritonavir |
| MVC | maraviroc |
| NFV | nelfinavir |
| NVP | nevirapine |
| RAL | raltegravir |
| RPV | rilpivirine |
| RTV or r | ritonavir |
| SQV | saquinavir |
| T-20 | enfuvirtide |
| TAF | tenofovir alafenamide |
| TDF | tenofovir disoproxil fumarate |
| TFV | tenofovir |
| TFV-DP | tenofovir-diphosphate |
| TMP-SMX | trimethoprim-sulfamethoxazole |
| TPV | tipranavir |
| TPV/r | tipranavir/ritonavir |
| ZDV | zidovudine |

# General Terms

| Abbreviation | Definition |
|---|---|
| AASLD | American Association for the Study of Liver Diseases |
| ACA | Affordable Care Act |
| ACC | American College of Cardiology |
| ACE | adverse childhood experience |
| ACTG | AIDS Clinical Trials Group |
| ADA | adenosine deaminase |
| ADAP | AIDS Drug Assistance Program |
| AE | adverse event |
| Ag/Ab | antigen/antibody |
| AHA | American Heart Association |
| AHC-HRSN | Accountable Health Communities Health-Related Social Needs |
| aHR | adjusted hazard ratio |
| Al | aluminum |
| ALT | alanine aminotransferase |
| AMP | average manufacturer price |
| anti-HBc | hepatitis B core antibody |
| anti-HBe | hepatitis B e antibody |
| anti-HBs | hepatitis B surface antibody |
| ApoB | apolipoprotein B |
| ART | antiretroviral therapy |
| ARTAS | Anti-Retroviral Treatment and Access to Services |
| ARV | antiretroviral |
| ASAM | American Society of Addiction Medicine |
| ASP | average sales price |
| ASCVD | atherosclerotic cardiovascular disease |
| AST | aspartate aminotransferase |
| ATI | analytical treatment interruption |
| AUD | alcohol use disorder |
| AUDIT-C | Alcohol Use Disorders Identification Test-Consumption |
| AV | atrioventricular |
| AWP | average wholesale price |

| Abbreviation | Definition |
|---|---|
| AYA | adolescents and young adults |
| BMD | bone mineral density |
| BMI | body mass index |
| BMT | bone marrow transplant |
| BUN | blood urea nitrogen |
| Ca | calcium |
| CAC | coronary artery calcium |
| CAP | cost-sharing assistance program |
| CBC | complete blood count |
| CCR5 | C-C chemokine receptor type 5 |
| CD4 | CD4 T lymphocyte |
| CDC | Centers for Disease Control and Prevention |
| CI | confidence interval<br>capsid inhibitor |
| CKD | chronic kidney disease |
| CKM | cardiovascular-kidney-metabolic |
| Cl | chloride |
| CMS | Centers for Medicare & Medicaid Services |
| CMV | cytomegalovirus |
| CNICS | Center for AIDS Research Network of Integrated Clinical Systems |
| CNS | central nervous system |
| CPI-U | consumer price index-urban |
| CPK | creatine phosphokinase |
| Cr | creatinine |
| CrCl | creatinine clearance |
| CsA | cyclosporine |
| CSF | cerebrospinal fluid |
| CV | cardiovascular |
| CVD | cardiovascular disease |
| CYP | cytochrome P450 |
| D/M | dual/mixed |
| DAA | direct-acting antiviral |
| dCK | deoxycytidine kinase |

| Abbreviation | Definition |
|---|---|
| DDI | drug–drug interaction |
| DILI | drug-induced liver injury |
| DM | diabetes mellitus |
| DMPA | depo-medroxyprogesterone acetate |
| DRESS | drug reaction with eosinophilia and systemic symptoms |
| DRM | drug resistance mutation |
| DOT | directly observed therapy |
| DSMB | Data Safety Monitoring Board |
| EBV | Epstein-Barr virus |
| eGFR | estimated glomerular filtration rate |
| EI | entry inhibitor |
| ESRD | end-stage renal disease |
| FCP | federal ceiling price |
| FDA | U.S. Food and Drug Administration |
| FDC | fixed-dose combination |
| Fe | iron |
| FPL | federal poverty level |
| GAD | Generalized Anxiety Disorder [test] |
| GHB | gamma-hydroxybutyrate |
| GI | gastrointestinal |
| GIP | glucose-dependent insulinotropic polypeptide |
| GLP-1 | glucagon-like peptide-1 |
| gp120 | glycoprotein 120 |
| GVHD | graft versus host disease |
| H2 | histamine type 2 |
| HAV | hepatitis A virus |
| HbA1C | hemoglobin A1c |
| HBcAb | hepatitis B core antibody |
| HBeAg | hepatitis B e antigen |
| HBsAb | hepatitis B surface antibody |
| HBsAg | hepatitis B surface antigen |
| HBV | hepatitis B virus |
| HCC | hepatocellular carcinoma |

| Abbreviation | Definition |
|---|---|
| $HCO_3$ | bicarbonate |
| HCT | hematopoietic cell transplant |
| HCV | hepatitis C virus |
| HD | hemodialysis<br>high-dose |
| HDL | high-density lipoprotein |
| HDV | hepatitis D virus |
| HHS | U.S. Department of Health and Human Services |
| HIPAA | Health Insurance Portability and Accountability Act |
| HIV | human immunodeficiency virus |
| HIV RNA | HIV viral load |
| HIV-1 | human immunodeficiency virus type 1 |
| HIV-2 | human immunodeficiency virus type 2 |
| HIVMA/IDSA | HIV Medicine Association of the Infectious Diseases Society of America |
| HLA | human leukocyte antigen |
| HMG-CoA | hydroxy-methylglutaryl-coenzyme A |
| HPTN | HIV Prevention Trials Network |
| HR | hazard ratio |
| HRSA | Health Resources and Services Administration |
| HRT | hormone replacement therapy |
| hsCRP | high-sensitivity C-reactive protein |
| HSR | hypersensitivity reaction |
| $IC_{50}$ | median inhibitory concentration |
| IDSA | Infectious Diseases Society of America |
| IL-2 | Interleukin-2 |
| IL-6 | Interleukin-6 |
| IL-7 | Interleukin-7 |
| IM | intramuscular |
| IN | integrase |
| INSTI | integrase strand transfer inhibitor |
| IPT | isoniazid preventive therapy |
| IRA | Inflation Reduction Act |
| IRIS | immune reconstitution inflammatory syndrome |

| Abbreviation | Definition |
|---|---|
| IUD | intrauterine device |
| IV | intravenous |
| K | potassium |
| LA | long-acting |
| LDL or LDL-C | low-density lipoprotein or low-density lipoprotein cholesterol |
| LLOD | lower limits of detection |
| Lp(a) | lipoprotein(a) |
| LTBI | latent tuberculosis infection |
| MACE | major adverse cardiovascular events |
| MASLD | metabolic dysfunction–associated steatotic liver disease |
| MATE1 | multidrug and toxic compound extrusion 1 |
| MDMA | methylenedioxymethamphetamine |
| MDR | multidrug resistant |
| MDR-TB | multidrug-resistant tuberculosis |
| MDRP | Medicaid Drug Rebate Program |
| Mg | magnesium |
| MHC | major histocompatibility complex |
| MI | myocardial infarction |
| MMP | Medication Monitoring Project |
| MRI | magnetic resonance imaging |
| MSM | men who have sex with men |
| MTR | multi-tablet regimen |
| N/A | not applicable |
| Na | sodium |
| NADAC | National Average Drug Acquisition Cost |
| NASTAD | National Alliance of State & Territorial AIDS Directors |
| NIH | National Institutes of Health |
| NNRTI | non-nucleoside reverse transcriptase inhibitor |
| NRT | nicotine replacement therapy |
| NRTI | nucleoside/nucleotide reverse transcriptase inhibitor |
| NTD | neural tube defect |
| OARAC | Office of AIDS Research Advisory Council |
| OBR | optimized background regimen |

| Abbreviation | Definition |
|---|---|
| OCT2 | organic cation transporter 2 |
| OI | opportunistic infection |
| OR | odds ratio |
| OTP | opioid treatment program |
| OUD | opioid use disorder |
| P | phosphorus |
| P-gp | p-glycoprotein |
| PAP | patient assistance program |
| PBM | pharmacy benefit manager |
| PCE | Pooled Cohort Equations |
| PCR | polymerase chain reaction |
| PDE5 | phosphodiesterase type 5 |
| PEP | post-exposure prophylaxis |
| PHQ | Patient Health Questionnaire |
| PI | protease inhibitor |
| PI/c | cobicistat-boosted protease inhibitor |
| PI/r | ritonavir-boosted protease inhibitor |
| PK | pharmacokinetic |
| PO | orally |
| PPI | proton pump inhibitor |
| PR | protease |
| PRAPARE | Protocol for Responding to and Assessing Patients' Assets, Risks, and Experiences |
| PrEP | pre-exposure prophylaxis |
| PREVENT | Predicting Risk of CVD EVENTs |
| PTH | parathyroid hormone |
| QTc | QT corrected for heart rate |
| RA | receptor agonist |
| RAPID | Rapid ART Program Initiative for HIV Diagnoses |
| REPC | Retention through Enhanced Personal Contact |
| RNA | ribonucleic acid |
| RT | reverse transcriptase |
| RWHAP | Ryan White HIV/AIDS Program |

| Abbreviation | Definition |
|---|---|
| SAMHSA | Substance Abuse and Mental Health Services Administration |
| SCr | serum creatinine |
| SDOH | social determinants of health |
| SJS | Stevens-Johnson syndrome |
| SMR | sexual maturity rating |
| SOT | solid organ transplantation |
| SPT | skin patch test |
| SQ | subcutaneous |
| SSP | syringe service program |
| STI | sexually transmitted infection |
| STR | single-tablet regimen |
| SUD | substance use disorder |
| TasP | treatment as prevention |
| TB | tuberculosis |
| TC | total cholesterol |
| TDM | therapeutic drug monitoring |
| TDR | transmitted drug resistance |
| TEN | toxic epidermal necrolysis |
| TG | triglyceride |
| the Panel | the Panel on Antiretroviral Guidelines for Adults and Adolescents |
| U=U | Undetectable = Untransmittable |
| UGT | uridine diphosphate glucuronosyltransferase |
| UGT1 | uridine diphosphate glucuronosyltransferase 1 family |
| UGT1A1 | uridine diphosphate glucuronosyltransferase 1A1 |
| ULN | upper limit of normal |
| USPSTF | U.S. Preventive Services Task Force |
| UW | University of Washington |
| VAT | visceral adipose tissue |
| WAC | wholesale acquisition cost |
| WBC | white blood cell |
| WHO | World Health Organization |
| Zn | zinc |

# Study and Trial Names

| Acronym/Abbreviation | Name |
|---|---|
| 2SD | Second-line Switch to Dolutegravir |
| ACTG | Advancing Clinical Therapeutics Globally |
| ADVANCE | Assessing Donor Variability And New Concepts in Eligibility |
| ANRS | National Agency for AIDS Research (France) |
| ARDENT | AIDS Clinical Trial Group study A5257 |
| ARTEMIS | Affordability and Real-World Antiplatelet Treatment Effectiveness After Myocardial Infarction Study |
| ATHENA | AIDS Therapy Evaluation in the Netherlands |
| ATLAS | Antiretroviral Therapy as Long-Acting Suppression |
| BRAAVE | B/F/TAF Regimen for African Americans with HIV and Virologically Suppressed/Treatment Experienced |
| CANTOS | Canakinumab Anti-Inflammatory Thrombosis Outcomes Study |
| CARES | Cabotegravir and Rilpivirine Efficacy and Safety |
| CoRECT | Cooperative Re-Engagement Controlled Trial |
| D:A:D | Data Collection on Adverse Events of Anti-HIV Drugs |
| $D^2$EFT | Dolutegravir and Darunavir Evaluation in Adults Failing Therapy |
| ECHO | Evidence for Contraceptive Options in HIV |
| FLAIR | First Long-Acting Injectable Regimen |
| LATITUDE | Long-Acting Therapy to Improve Treatment Success in Daily LifE |
| NA-ACCORD | North American AIDS Cohort Collaboration on Research and Design |
| NADIA | Nucleosides And Darunavir/Dolutegravir In Africa |
| PARTNER | Partners of People on ART: a New Evaluation of the Risks |
| RESPOND | International Cohort Consortium of Infectious Disease |
| REPRIEVE | Randomized Trial to Prevent Vascular Events in HIV |
| SMART | Strategies for Management of Antiretroviral Therapy |
| SOLAR | Switch Onto Long-Acting Regimen |
| STaR | Study of Treatment and Reproductive Outcomes |
| START | Strategic Timing of AntiRetroviral Treatment |
| TEMPRANO | Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults |
| THRIVE | Targeting HIV Retention and Improved Viral Load Through Engagement |
| VACS | Veterans Aging Cohort Study |
| WIHS | Women's Interagency HIV Study |